Back to News
Market Impact: 0.15
Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression
Source: marketbeat.com
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Helus Pharma, formerly Cybin (NASDAQ: HELP), presented late-stage development plans for HLP-003 as an adjunctive treatment for major depressive disorder at TD Cowen's neuropsychiatry summit. The company also discussed its broader pipeline of serotonergic agonists, but disclosed no clinical data, regulatory milestones, or financial guidance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
HELP0.20
More News
- Japan approval, a 27% surge: the diagnostics stock our models picked in September
- Oracle Japan shares surge 7% after record fiscal first quarter, bucking selloff of U.S. parent
- Costco makes progress on a key membership metric. Here's our new price target on the stock
- Akamai secures $11.6B cloud deal with Anthropic for AI workloads
- Tesla poised to scale production of heavy-duty Semi trucks with opening of Nevada factory
- Why we like Starbucks’ latest turnaround move — plus, two more wins for Eli Lilly
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Capital IQ Alternatives for Research and Deal Work
- Research Workflows, Report Format Selection, and Interactive Synthesis